Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus.
OBJECTIVE
Although clear peripheral nerve pathological abnormalities have been demonstrated in diabetic peripheral neuropathy (DPN), there is little information with regard to brain involvement. Our aim was to use in vivo proton magnetic resonance specroscopy (H-MRS) in patients with DPN in order to assess the neuro-chemical status of the thalamus, which acts as the gateway to the brain for somatosensory information.


METHODS
Participants included 18 type 1 diabetic men (eight without DPN, ten with DPN) and six non-diabetic healthy volunteers, who all underwent detailed clinical and neurophysiological assessments yielding a Neuropathy Composite Score (NCS) derived from Neuropathy Impairment Score of the Lower Limbs plus seven tests of nerve function prior to investigation via a single-voxel H-MRS technique, which was used to sample ventral posterior thalamic parenchyma. Spectroscopic resonances including those due to N-acetyl aspartate (NAA) were assessed at both short and long echo-time, providing putative indicators of neuronal function and integrity, respectively.


RESULTS
At long echo-time we observed significantly lower NAA:creatine (p = 0.04) and NAA:choline (p = 0.02) ratios in DPN patients than in the other groups. No group differences were detected at short echo-time. We found a significant positive association between both sural amplitude (rho = 0.61, p = 0.004) and nerve conduction velocity (r = 0.58, p = 0.006) and NAA:creatine signal among participants with diabetes. Vibration detection threshold (rho = -0.70, p = 0.004) was significantly related to NAA:choline ratio. Heart rate variability with deep breathing (rho = -0.46, p = 0.05) and NCS (rho = -0.53, p = 0.03) were significantly related to NAA:creatine ratio.


CONCLUSIONS
The significantly lower NAA:creatine ratio in DPN is suggestive of thalamic neuronal dysfunction, while the lack of difference in short echo-time between the groups does not suggest neuronal loss. Taken together with the observed correlations between NAA and neurophysiological assessments, these findings provide evidence for thalamic neuronal involvement in DPN.
Selvarajah
D
D
Diabetes Research Unit, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK. dinesh.selvarajah@gmail.com
Wilkinson
I D
ID
Emery
C J
CJ
Shaw
P J
PJ
Griffiths
P D
PD
Gandhi
R
R
Tesfaye
S
S
D000328:Adult; D002794:Choline / Q000097:blood; D003404:Creatinine / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000503:physiopathology*; D007839:Functional Laterality; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D010525:Peripheral Nerves / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000503:physiopathology; D010543:Peroneal Nerve / Q000502:physiology / Q000503:physiopathology; D012016:Reference Values; D013497:Sural Nerve / Q000503:physiopathology; D013788:Thalamus / Q000502:physiology / Q000503:physiopathology*
D003404:Creatinine; D002794:Choline
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):477-82
9343127
Magn Reson Imaging. 1996;14(4):365-72
8782174
Diabetes Care. 2004 Jun;27(6):1458-86
15161806
Neurology. 1993 Aug;43(8):1508-12
8351003
Diabetes Care. 1988 Jul-Aug;11(7):592-7
3060328
Neuroscience. 1991;45(1):37-45
1754068
Br Heart J. 1986 Apr;55(4):348-54
3964501
Ann Neurol. 1998 Sep;44(3):334-40
9749599
Dev Neurosci. 1993;15(3-5):289-98
7805581
Muscle Nerve. 2003 Feb;27(2):202-10
12548528
Curr Opin Neurobiol. 1994 Aug;4(4):550-6
7812144
Brain. 1994 Feb;117 ( Pt 1):49-58
8149214
Diabetes Care. 2007 Oct;30(10):2752-3
17901534
NMR Biomed. 1991 Apr;4(2):47-52
1650241
Diabetes Care. 2006 Dec;29(12):2664-9
17130202